ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Intellia Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on April 14, 2025 [1]. Group 1: Class Action Details - Investors who purchased Intellia securities between July 30, 2024, and January 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that Intellia provided misleading information regarding its Phase 1/2 study for NTLA-3001, failing to disclose the declining demand for viral-based editing methods [5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].